Effect of oral administration of protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on the growth of 3-methylcholanthrene-induced carcinoma in mice.
Oral administration of a synthetic protease inhibitor. [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate, was used to challenge 3-methylcholanthrene-induced carcinoma. This drug was administered 3 times daily via a stomach tube at doses of 12.5, 25 and 50 mg/kg in 33 mice harboring solid tumors. Oral administration of more than 50.0 mg/kg of this protease inhibitor significantly inhibited tumor growth and prolonged the survival time of cancer-harboring animals (P les than 0.05). These results indicate that oral administration of an inhibitor of kinin-forming protease has an antitumor effect on malignant tumors.